| Trial ID: | L4714 |
| Source ID: | NCT04523064
|
| Associated Drug: |
Empagliflozin 25 Mg
|
| Title: |
POST-CABGDM: Empagliflozin in Perioperative CABG
|
| Acronym: |
POST-CABGDM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Coronary Artery Disease|Coronary Artery Bypass Surgery|Acute Kidney Injury
|
| Interventions: |
DRUG: Empagliflozin 25 MG
|
| Outcome Measures: |
Primary: Acute kidney injury, Development of post-CABG acute kidney injury according to RIFFLE or AKIN or KDIGO criteria, 3 months | Secondary: Atrial fibrillation, Development of atrial fibrillation during hospital admission, 3 months|Pulmonary infection, Development of pulmonary infection during hospital admission, 3 months|Infection of surgical site, Development of infection of surgical site during hospital admission, 3 months|ICU readmission, Transfer to ICU during hospital admission, 3 months|Need for IV insulin, Need for IV insulin during hospital admission, 3 months|Myocardial Infarction Type 5, Occurence of myocardial infarction type 5 during admission, 3 months
|
| Sponsor/Collaborators: |
Sponsor: University of Sao Paulo General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
155
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-09-22
|
| Completion Date: |
2024-01-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-06-10
|
| Locations: |
University of Sao Paulo Medical School - The Heart Institute, Sao Paulo, SP, 05403010, Brazil
|
| URL: |
https://clinicaltrials.gov/show/NCT04523064
|
